Colorectal cancer poop
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Colorectal Cancer Detection through Stool Analysis
Stool Microbiome and Metabolome in Colorectal Cancer
Recent research has highlighted significant differences in the stool microbiome and metabolome between colorectal cancer (CRC) patients and healthy individuals. A study conducted at the University of Colorado Health-Poudre Valley Hospital analyzed stool samples from both groups to identify specific bacterial and metabolic markers associated with CRC.
Microbial Community Structure
The study found no significant differences in the overall microbial community structure between CRC patients and healthy controls. However, certain bacterial genera showed notable variations. Butyrate-producing species were under-represented in CRC samples, while the mucin-degrading species, Akkermansia muciniphila, was approximately four times higher in CRC patients (p<0.01).
Metabolite Differences
In terms of metabolites, healthy individuals had higher levels of butyrate in their stool, whereas CRC patients exhibited higher relative concentrations of acetate. Additionally, CRC patients' stool samples contained higher concentrations of amino acids, while healthy individuals had higher levels of poly and monounsaturated fatty acids and ursodeoxycholic acid, a conjugated bile acid (p<0.01). These findings suggest that specific microbial functions and their associated metabolites could play a role in CRC development and may serve as potential therapeutic targets.
DNA Alterations in Stool for Colorectal Cancer Screening
Another promising approach for CRC detection involves analyzing altered human DNA in stool samples. A study explored the feasibility of using a multitarget assay panel to detect DNA alterations in stool, which could discriminate between individuals with colorectal neoplasia and those with normal colons.
Assay Methodology
The study analyzed stool samples from 22 CRC patients, 11 patients with adenomas ≥1 cm, and 28 individuals with endoscopically normal colons. The assay targeted point mutations at 15 sites on the K-ras, p53, and APC genes, as well as the Bat-26 microsatellite instability marker and highly amplifiable DNA.
Sensitivity and Specificity
The results were promising, with a sensitivity of 91% for cancer and 82% for adenomas ≥1 cm, and a specificity of 93%. When K-ras was excluded from the panel, the sensitivity for cancer remained unchanged, but the sensitivity for adenomas slightly decreased to 73%, while specificity increased to 100%. These findings indicate that altered DNA in stool could be a viable screening method for CRC, warranting further clinical investigations.
Conclusion
Both microbiome and metabolome profiling, as well as DNA alteration assays in stool, show significant potential for colorectal cancer detection. The identification of specific bacterial species and metabolites associated with CRC, along with the detection of altered DNA, could pave the way for non-invasive, effective screening methods. Future research and larger clinical trials are essential to validate these findings and develop reliable diagnostic tools for early CRC detection.
Sources and full results
Most relevant research papers on this topic